What type of study is this?

This is a Phase 1 study (also classified as: Phase 2, Human Clinical Trial).

December 10, 2017New England Journal of MedicineOpen Access

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

SNSattva S. NeelapuThe University of Texas MD Anderson Cancer Center FLFrederick L. LockeMoffitt Cancer Center NBNancy L. BartlettBoston University

Discussion

Member takes

Overview

Phase 2 trial demonstrated an 82% objective response rate in patients with refractory large B-cell lymphoma, indicating high efficacy of CAR T-cell therapy.

Key Points

The objective response rate was 82%, with a 54% complete response rate in patients receiving axi-cel therapy.
Among 111 enrolled patients, 40% maintained a complete response after a median follow-up of 15.4 months.
Patients were treated with a conditioning regimen followed by 2×106 anti-CD19 CAR T cells per kilogram.
High levels of CAR T-cells were linked to positive treatment responses, though adverse events included neutropenia and cytokine release syndrome.

Cite This Study

Neelapu et al. (2017) studied this question.

synapsesocial.com/papers/68f648ee33dca03d982ea4a7 https://doi.org/10.1056/nejmoa1707447

View Full Paper

Ask AI

Bookmark

December 10, 2017New England Journal of MedicineOpen Access

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

SNSattva S. NeelapuThe University of Texas MD Anderson Cancer Center FLFrederick L. LockeMoffitt Cancer Center NBNancy L. BartlettBoston University

Discussion

Member takes

Overview

Phase 2 trial demonstrated an 82% objective response rate in patients with refractory large B-cell lymphoma, indicating high efficacy of CAR T-cell therapy.

Key Points

The objective response rate was 82%, with a 54% complete response rate in patients receiving axi-cel therapy.
Among 111 enrolled patients, 40% maintained a complete response after a median follow-up of 15.4 months.
Patients were treated with a conditioning regimen followed by 2×106 anti-CD19 CAR T cells per kilogram.
High levels of CAR T-cells were linked to positive treatment responses, though adverse events included neutropenia and cytokine release syndrome.

Cite This Study

Neelapu et al. (2017) studied this question.

synapsesocial.com/papers/68f648ee33dca03d982ea4a7 https://doi.org/10.1056/nejmoa1707447

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark